Drugs for Chronic Closed-Angle Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 20)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Pilocarpine |
Approved, Investigational |
Phase 4 |
|
54-71-7, 92-13-7 |
5910 |
Synonyms:
(+)-Pilocarpine
(3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one
(3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
(3S,4R)-3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S,4R)-3-ethyldihydro-4-((1-Methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S-cis)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone
(3S-cis)-3-ethyldihydro-4-[(1-Methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone
3-ethyl-4-((1-methyl-1H-imidazol-5-yl)methyl)dihydro-2(3H)-furanone
3-Ethyl-4-(3-methyl-3H-imidazol-4-ylmethyl)dihydrofuran-2-one
3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydro-2(3H)-furanone
3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one
3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
54-71-7
91484-73-0
92-13-7
AC1L1J0W
AC1L1LEF
AC1Q6MOP
Adsorbocarpine
AI3-50523
Almocarpine
Amistura P
AR-1F3128
beta-Pilocarpine hydrochloride
BIDD:GT0217
BPBio1_000548
BRD-K85090592-008-05-2
BSPBio_000498
BSPBio_002191
C07474
CHEBI:39460
CHEBI:8207
CHEMBL550
CID4819
CID5910
D00525
DB01085
DivK1c_000358
EINECS 202-128-4
Epicar
HMS2089K17
HSDB 3163
Hydrochloride, pilocarpine
IDI1_000358
Imidazole-5-butyric acid, alpha-ethyl-beta-(hydroxymethyl)-1-methyl-, gamma-lactone
isopilocarpine
Isopilocarpine
Isopto carpine
Isoptocarpine
KBio1_000358
KBio2_001587
KBio2_004155
KBio2_006723
KBio3_001691
KBioGR_000956
KBioSS_001587
L001181
Lopac0_000950
Lopac0_000960
LS-187208
LS-7661
Minims Pilocarpine
Miocarpine
Mi-Pilo
MolPort-002-512-506
NCGC00023339-03
NCGC00023339-06
|
NCGC00023339-07
NCGC00023339-08
NCGC00023339-09
NCGC00023339-12
NCGC00023339-13
nchembio.78-comp9
NCI60_004403
NINDS_000358
Nitrate, pilocarpine
NSC5746
Ocu-Carpine
Ocusert
Ocusert P 20
Ocusert pilo
Ocusert pilo-20
Ocusert pilo-20 (TN)
Ocusert Pilo-40
P.V. Carpine Liquifilm
Pilagan
Pilocarpin
Pilocarpina
pilocarpine
Pilocarpine
Pilocarpine (JAN/USP)
Pilocarpine [USAN:BAN:JAN]
Pilocarpine chloride
Pilocarpine HCl
Pilocarpine HCL
Pilocarpine hydrochloride
Pilocarpine monohydrochloride
Pilocarpine mononitrate, (3S-cis)-isomer
Pilocarpine Mononitrate, (3S-cis)-Isomer
Pilocarpine muriate
Pilocarpine nitrate
Pilocarpine, monohydrochloride, (3S-cis)-isomer
Pilocarpine, Monohydrochloride, (3S-cis)-Isomer
Pilocarpol
Pilokarpin
Pilokarpin monohydrochloride
Pilokarpol
Piloptic-1
Piloptic-1/2
Piloptic-2
Piloptic-3
Piloptic-4
Piloptic-6
Pilostat
Prestwick0_000449
Prestwick1_000449
Prestwick2_000449
Prestwick3_000449
Salagen
SDCCGMLS-0003164.P005
SPBio_001287
SPBio_002437
Spectrum_001107
Spectrum2_001284
Spectrum3_000546
Spectrum4_000478
Spectrum5_001379
Spersacarpine
Spersacarpine hydrochloride
STOCK1N-18408
Syncarpine
Tocris-0694
UNII-01MI4Q9DI3
ZINC00075008
|
|
2 |
|
Travoprost |
Approved |
Phase 4 |
|
157283-68-6 |
5282226 |
Synonyms:
(((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(+)-Fluprostenol isopropyl ester
(1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate
157283-68-6
5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z)
AC1NQZOS
AC-6103
AL6221
AL-6221
C26H35F3O6
CHEBI:746859
CHEMBL1200799
CID5282226
D01964
DB00287
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
|
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
LS-173521
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
S1554_Selleck
Travatan
Travatan (TN)
Travatan Alcon
Travatan Z
Travatan, Travoprost
Travatanz
Travoprost
Travoprost (JAN/USAN/INN)
Travoprost [USAN]
Travoprostum
Z, Travatan
ZINC04474682
|
|
3 |
|
Latanoprost |
Approved, Investigational |
Phase 4 |
|
130209-82-4 |
5311221 5282380 |
Synonyms:
130209-82-4
AC1NSK8Q
Ambap130209-82-4
AR-202
Catioprost
CHEBI:6384
CHEMBL1051
CID5311221
CPD000466354
D00356
HMS2051H11
HMS2089J17
isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate
Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoic acid
Jsp001835
L1167_SIGMA
latanoprost
Latanoprost
Latanoprost (JAN/USAN/INN)
latanoprost free acid
Latanoprostum
MLS000759468
|
MLS001424106
MolPort-003-942-862
Nova-21027
Pfizer brand OF latanoprost
PhXA 41
PhXA34
PhXA34 [as 15(R,S)-isomer]
PhXA41
PHXA41
PHXA-41
propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoic acid
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
S1254_Selleck
SAM001246671
SMR000466354
TL8000716
XA41
XA-41
Xalatan
Xalatan (TN)
Xalatan Fixed Flow Device
ZINC12468792
|
|
4 |
|
Timolol |
Approved |
Phase 4 |
|
26839-75-8 |
5478 33624 |
Synonyms:
(-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole
(2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol
(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol
(S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol
(S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(S)-timolol
131628-37-0
194288-09-0
26839-75-8
26921-17-5 (maleate (1:1) salt)
AB00513729
AC1L1PYN
AC1Q59QM
Apo-Timol
Apo-Timop
Aquanil
Betim
Betimol
Betimol (TN)
BIDD:GT0073
Blocadren
BPBio1_001008
BRD-K08806317-050-03-6
BSPBio_000916
C07141
C13H24N4O3S
CAS-26921-17-5
CHEBI:9599
CHEMBL499
CID33624
CPD001456519
D08600
DB00373
DB08625
EINECS 248-032-6
HMS2089I11
HSDB 6533
Istalol
L-714,465
Lopac0_001189
Lopac-T-6394
LS-122231
MK-950
NCGC00016038-01
NCGC00016038-02
|
NCGC00016798-01
NCGC00016798-07
NCGC00022033-02
NCGC00022033-04
NCGC00022033-05
Novo-Timol
Nu-Timolol
Oprea1_640981
Optimol
Phoxal-timolol
Prestwick0_000948
Prestwick1_000948
Prestwick2_000948
Prestwick3_000948
Proflax
S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole
S(-)-Timolol maleate
SAM002564238
SPBio_003075
ST072193
Temserin
Tenopt
TIM
Timacar
Timacor
Tim-AK
timolol
Timolol
Timolol (INN)
Timolol (TN)
Timolol [USAN]
Timolol anhydrous
Timolol GFS
Timolol maleate
Timolol Maleate, (1:1) Salt
Timololo
Timololum
Timololum [INN-Latin]
Timopic
Timoptic
Timoptic in Ocudose
Timoptic OcuDose
Timoptic-XE
Timoptol
Tocris-0649
UNII-817W3C6175
|
|
5 |
|
Brinzolamide |
Approved |
Phase 4 |
|
138890-62-7 |
68844 |
Synonyms:
(+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE
(4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
(4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
(R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide
(R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide
138890-62-7
2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide,4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide,R
3znc
AB00513824
AC1L2AKA
AC1Q6UVB
AC-5277
AKOS005145708
AL 4862
AL04862
AL-4862
Alcon brand of brinzolamide
Alcon brand OF brinzolamide
Allphar brand of brinzolamide
Allphar brand OF brinzolamide
Azopt
Azopt (TN)
BIDD:GT0039
Birnzolamide
BPBio1_000539
BRD-K74913225-001-03-3
Brinzolamida
|
Brinzolamide
Brinzolamide (BRZ)
Brinzolamide (JAN/USP/INN)
Brinzolamide [USAN]
BSPBio_000489
BZ1
C07760
C111827
C12H21N3O5S3
CHEBI:3176
CHEMBL220491
CID68844
D00652
DB01194
FT-0082471
HMS1569I11
I09-0605
LS-173036
MLS002153787
MolPort-005-940-291
Prestwick0_000365
Prestwick1_000365
Prestwick2_000365
Prestwick3_000365
SMR001233169
SPBio_002410
UNII-9451Z89515
|
|
6 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
7 |
|
Muscarinic Agonists |
|
Phase 4 |
|
|
|
8 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
9 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
10 |
|
Ophthalmic Solutions |
|
Phase 4 |
|
|
|
11 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
12 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
13 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
14 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
15 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
16 |
|
Adrenergic beta-Antagonists |
|
Phase 4 |
|
|
|
17 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
18 |
|
Brimonidine Tartrate |
|
Phase 4 |
|
70359-46-5 |
|
19 |
|
Carbonic Anhydrase Inhibitors |
|
Phase 4 |
|
|
|
20 |
|
Bimatoprost |
Approved, Investigational |
|
|
155206-00-1 |
5311027 |
Synonyms:
(5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
155206-00-1
15M
267244-98-4
5-Heptenamide,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ehtyl-,(5Z)
AC1NSJUW
AGN 192024
AGN-192024
Bimataprost [USAN:INN:BAN]
Bimatoprost
Bimatoprost (JAN/USAN/INN)
Bimatoprost [USAN:INN:BAN]
bimatoprostum
Bimatoprostum
|
CHEBI:39562
CHEBI:51230
CHEMBL1200963
CID5311027
D02724
DB00905
DB06863
I06-1275
I06-1277
Latisse
LS-181817
Lumigan
Lumigan (TN)
NCGC00181745-01
UNII-QXS94885MZ
ZINC04474405
|
|
Interventional clinical trials:
(show all 12)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Twelve-Week, Double Masked, Parallel Group, Primary-Therapy Pilot Study of the Safety and Efficacy of Travoprost 0.004% Compared to Pilocarpine 1% in Patients With Chronic Angle-Closure Glaucoma |
Completed |
NCT00762645 |
Phase 4 |
Travoprost 0.004% (Travatan);Pilocarpine 1% |
2 |
An 8 Week, Single Masked, Parallel-Group, Exploratory Study Comparing Ocular Surface Signs and Symptoms in Monotherapy Ocular Hypertension or Glaucoma Patients Randomized to Either Xalatan® or Travatan Z® |
Completed |
NCT00799682 |
Phase 4 |
Xalatan;Travatan Z |
3 |
Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients |
Terminated |
NCT01151904 |
Phase 4 |
brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution;latanoprost |
4 |
A Double-Masked, Parallel-Group, Efficacy and Safety Study of Brinzolamide 1.0% (AZOPT) as Adjunctive Therapy to Travoprost 0.004% (TRAVATAN) in Patients With Chronic Angle-Closure Glaucoma |
Terminated |
NCT00758342 |
Phase 4 |
Travoprost 0.004% + Brinzolamide 1.0%;Travoprost 0.004% + Tears Natural |
5 |
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma. |
Completed |
NCT00051181 |
Phase 3 |
Travoprost (0.004%);Latanoprost (0.005%) |
6 |
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma |
Unknown status |
NCT02152774 |
Phase 2 |
Rho-Kinase Inhibitor |
7 |
Prevalence of Chronic Angle Closure in Caucasian Hyperopic Subjects |
Unknown status |
NCT00823706 |
|
|
8 |
Comparison of Bimatoprost and Lataprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study |
Unknown status |
NCT00567788 |
|
Latanoprost-Bimatoprost;Bimatoporost-Latanoprost |
9 |
Biometric Indicators of Eyes With Occult Lens Subluxation |
Completed |
NCT03752710 |
|
|
10 |
Angle Closure: Laser Iridotomy Versus Phacoemulsification Study (ACLIPS)- A Study of Acute Primary Angle Closure Glaucoma Comparing Two Treatment Modalities: Laser Peripheral vs Phacoemulsification With Posterior Intraocular Lens Implant |
Completed |
NCT00350428 |
|
|
11 |
Comparison Study of Glaucoma Eye Care Follow-Up Adherence in a High Risk Population |
Completed |
NCT02347670 |
|
|
12 |
Sequential Laser Iridotomy Using Argon and Q-Switched 532 nm Frequency Doubled Neodymium Yag Laser: A Pilot Study |
Completed |
NCT00452998 |
|
|
|